CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 июл 2022 17:09:22 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 июн 2022 16:30:47 Источник Nasdaq GlobeNewswire

Crinetics Presents Clinical and Research Results at ENDO 2022

08 июн 2022 07:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

07 июн 2022 07:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

25 май 2022 07:00:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

12 май 2022 16:41:57 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 май 2022 16:18:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

18 апр 2022 16:01:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

12 апр 2022 23:52:43 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 апр 2022 17:15:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

30 мар 2022 16:02:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

30 мар 2022 16:01:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer

21 мар 2022 07:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 мар 2022 17:20:34 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer

01 мар 2022 08:00:18 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan

28 фев 2022 06:00:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

09 фев 2022 07:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 фев 2022 16:42:26 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

12 янв 2022 07:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

05 янв 2022 07:30:00 Источник Nasdaq GlobeNewswire